Abstract
Interferon is widely used as the most effective agent in the adjuvant therapy of patients with melanoma. However, little is known about the effect of intermediate dose interferon (IDI) in adjuvant therapy. We conducted this study to determine whether intermediate doses of interferon-alpha 2 could be beneficial for these patients. A series of 84 melanoma patients with high-risk relapse potential (stage II–III) after excisional biopsy were enrolled for adjuvant therapy with IDIs, either IFN-alpha 2a, 9 MU or IFN alpha 2b, 10 MU per day, subcutaneously, for 1 yr consisted of an induction period (5 d/wk for 4 wk) followed by 48 wk of same dose administered three times per week. The median follow-up was 25.9 mo, with range 4−90.4 mo. Thirty-three (39%) patients had progressed; 18 (55%) of them while on treatment. The median (range) time of the failure occurrence was 9.1 mo (1.7−47.3 mo). Distribution of failure site was identical and the majority of the recurrences were found as single metastasis. For distant metastasis-free interval, mean (±SE) value was 28.8±3.6 mo; 1− and 2−yr survival rates were 87.8±5.7% and 61.6±9.3%, respectively. Twenty-two deaths were observed. Five-year survival rates of progression-free survival and overall survival were 50% and 60%, respectively. Generally, the treatment was found well-tolerated; drug-induced dose reduction or treatment discontinuation due to toxicity was minimal. Severe toxicity was rare. In conclusion, the small number of patients and the short follow-up does not permit any conclusion. However, the preliminary data seem to show that treatment with IDI was usually well tolerated with low toxicity of the patients during the adjuvant therapy.
Similar content being viewed by others
References
Gray RJ, Pockaj BA, Kirkwood JM. An update on adjuvant interferon for melanoma. Cancer Control 2002; 9: 16–21.
McClay EF. Adjuvant therapy for patients with high-risk malignant melanoma. Semin Oncol 2002; 29: 389–399.
Eggermont AMM, Gore M. European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma. Semin Oncol 2002; 29: 382–388.
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996; 14: 7–17.
Eggermont AMM, Kleeberg UR, Ruiter DJ, Suciu S. European Organization for Research and Treatment of Cancer Melanoma Group Trial experience with more than 2000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b. ASCO Educational Book 2001, pp. 88–93.
Dawes M, Lens MB. Interferon alfa therapy for malignant melanoma: a systemic review of randomized controlled trials. J Clin Oncol 2002; 20: 1818–1825.
Sabel MS, Sondak VK. Pros and cons of adjuvant interferon in the treatment of melanoma. Oncol Spectrums 2002; 3: 264–270.
http://www.cancer.gov/cancertopics/pdq/treatment/ melanoma/healthprofessional.
Kirkwood JM, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of Intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444–2454.
Kirkwood JM, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup Trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370–2380.
Jost M, Jelic S, Purkalne G. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanoma Ann Oncol 2005; 16 (suppl 1): i66-i68.
Eggermont AMM, et al. Update of EORTC melanoma trials. Final results of the EORTC melanoma group trials: EORTC 18951 in stage IV and EORTC 18952 in stage IIB-III. Melanoma Res 2004; 14: A11-A12.
Eggermont AMM, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomisezed controlled trial. Lancet 2005; 366: 1189–1196.
Ascierto PA, et al. Intermediate dose recombinant interferon-α as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon. Cancer 2000; 89: 1490–1494.
Savio G, et al. Intermediated dose interferon alpha 2b(IFN alpha 2b) in adjuvant treatment for malignant melanoma. Melanoma Res 2004; 14: S23-S24.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tas, F., Kurul, S., Camlica, H. et al. Intermediate dose interferon alpha in adjuvant treatment for high-risk melanoma. Med Oncol 23, 471–477 (2006). https://doi.org/10.1385/MO:23:4:471
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/MO:23:4:471